Skip to main content
Donate

Molecular Tuning of Next-Generation Oligonucleotides to Treat Angelman Syndrome

$360,000 2026 FT2026-001

Molecular Tuning of Next-Generation Oligonucleotides to Treat Angelman Syndrome

Our cells use DNA and RNA as instruction manuals to make proteins that our body needs to function. In disorders like Angelman syndrome (AS), errors in DNA or RNA can lead to the wrong instructions. This can result in the body producing too much, too little, or non-functional proteins. This can cause serious health problems. Scientists have developed special treatments called antisense oligonucleotides (ASOs) to help fix these mistakes. ASOs are made by stringing together building blocks called bases. Current

drugs that are being developed for AS use specialty bases, chemistries and modifications to improve the drug delivery and penetration to cells. These ASOs in the clinic need to be injected directly into the spinal fluid multiple times a year because they are metabolized and don't last more than a couple of months after the injection. Theoretically, these drugs can be modified through chemical reactions and new building blocks. This team aims to engineer the enzymes to make new building blocks with more efficiency. The learnings may provide researchers with new opportunities for next generation ASO therapies that last longer.

Principle Investigator

Frances Arnold, PhD

Frances Arnold is the Linus Pauling Professor of Chemical Engineering, Bioengineering, and Biochemistry at the California Institute of Technology. She was awarded the Nobel Prize in Chemistry in 2018 for pioneering directed enzyme evolution and has used directed protein evolution for applications in alternative energy, chemicals, and medicine. Her lab is developing new methods of machine-learning guided enzyme evolution and exploring non-natural enzyme reactivities. Her work has been recognized with numerous awards, including the Charles Stark Draper Prize of the National Academy of Engineering (2011), the National Medal of Technology and Innovation (2011), and the Millennium Technology Prize (2016). She has been elected to the National Academies of Science, Medicine, and Engineering and was appointed to the Pontifical Academy of Sciences by Pope Francis in 2019. She served as co-chair of President Biden’s Council of Advisors on Science and Technology from 2021-2025. Arnold earned her BS in Mechanical and Aerospace Engineering from Princeton University and PhD in Chemical Engineering from the University of California, Berkeley.

Frances Arnold, PhD

Disclaimer

This website contains information for a broad audience and may include information on current and upcoming programs that are not yet approved or accessible The information provided is for general informational purposes only and is not intended as medical advice, diagnosis, or treatment. While FAST strives to provide accurate and up-to-date information, the content on this site may not always reflect the most current research or clinical guidelines. The inclusion of clinical trial information, treatments or specific healthcare providers does not imply endorsement, recommendation or guarantee of safety, efficacy, or availability. Reliance on any information provided by this website is solely at your own risk. FAST disclaims any liability for any errors or omissions in the information provided or for any decisions made based on this information. For personalized medical advice or specific health concerns including participation in any clinical trial, please consult a qualified healthcare professional.